Stay updated on Pediatric Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Pediatric Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pediatric Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:12:04.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of nanoparticle albumin-bound rapamycin administered in combination with temozolomide and irinotecan hydrochloride for pediatric patients with recurrent or refractory solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:21.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes a detailed explanation of eligibility criteria, such as a person's general health condition or prior treatments, and provides a link for general information about clinical research.
    Difference
    50%
    Check dated 2024-05-22T20:59:34.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:53:17.000Z thumbnail image

Stay in the know with updates to Pediatric Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pediatric Solid Tumors Clinical Trial page.